患有高LDL-C和高血小板反应率的患者的非他类药物治疗:叙述性综述
F N Nurmukhammad1, B Zhangelova Sh2, D A Кapsultanova3
1H.A. Yasawi International Kazakh-Turkish University, Turkestan, Republic of Kazakhstan.
The Medical journal of Malaysia
|March 27, 2025
概括
高LDL-C与高残留血小板反应率 (HRPR) 之间的联系的研究是有限的. 较新的疗法和个性化治疗计划对于在患有血脂障碍和HRPR的患者中控制心血管风险至关重要.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 升高的LDL-C和高残留血小板反应率 (HRPR) 是常见的,并且独立地加速动脉样硬化.
- 关于高LDL-C和HRPR之间的关联的证据有限,特别是在亚最佳的降脂疗法下.
研究的目的:
- 审查目前关于LDL-C水平和HRPR之间的关系的证据.
- 探索新型疗法在治疗失脂症和HRPR患者心血管风险中的作用.
- 突出需要个性化治疗策略的需要.
主要方法:
- 对随机对照试验 (RCT) 的电子数据库进行系统搜索.
- 包括具有高度科学新性,可靠结果和强大的方法论的研究.
- 对LDL-C和HRPR对结果的影响进行了随机效应元分析.
主要成果:
- 像英克利西兰和PCSK9抑制剂这样的新疗法对高风险患者来说是有希望的.
- 达到目标的LDL-C水平和管理HRPR仍然是重大的临床挑战.
- 抗血小板和降脂疗法的最佳组合需要进一步研究.
结论:
- 个性化,多学科的方法是必要的,以优化冠心病患者的抗血小板和降脂疗法.
- 个性化治疗可以降低复发性心血管事件的风险.
- 进一步的研究是必要的,以阐明LDL-C和HRPR之间的复杂关系.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


